A senior ICMR official told a parliamentary panel on Wednesday that the phase two clinical trial of two locally evolved COVID-19 vaccine applicants is approaching the final touch and that emergency approval of a vaccine can be considered as if the Center decided, according to an ITP. Report.
The Director-General of the Medical Research Council of India (ICMR), Balram Bhargava, has informed the members of the Standing Parliamentary Committee on Internal Affairs that candidate vaccines evolved through Bharat Biotech, Cadila and the Serum Institute of India are in other stages of testing. said an MP provide at the meeting, PTI reported.
When asked when we would have a COVID-19 vaccine, the deputy said that Bhargava replied that the final trial takes six to nine months, but that if governments decide, an emergency authorization can be considered, according to the PTI news agency.
CoVID-19 candidate vaccines coordinated through Bharat Biotech and Zydus Cadila are near the finishing touch of phase II trials. Meanwhile, the Serum Institute of India is able to initiate the Phase II trial of the COVID-19 vaccine developed through the University of Oxford and AstraZeneca. The Swedish British company has partnered with IBS to manufacture vaccines for India and low- and middle-income countries.
“I need to tell other people that the skill of our scientists is like that of ‘rishi equipped’ and that they work very hard in laboratories. Three vaccines are in other stages of testing. When scientists give us the green signal, it will be produced on a giant scale and all the arrangements have been made for it,” Prime Minister Narendra Modi said as he was heading to the country on Independence Day.
The Pune-based drug manufacturer decided at 17 sites in India to conduct the trial. These sites include: Andhra Medical College (Visakhapatnam), JSS Academy of Higher Education and Research, (Mysore), Seth GS Medical College and KEM Hospital (Mumbai), KEM Hospital Research Center (Vadu), BJ Medical College and Sassoon General Hospital (Pune), All India Institute of Medical Sciences (Jodhpur), Rajendra Memorial Research Institute of Medical Sciences, (Patna), Institute of Medical Medicine (Madras), Post Institute of Graduate Institute of Medical Education – Research (PGIMER) Array Bharati Vidyapeeth University College , Jehangir Hospital (Pune), AIIMS (Delhi), ICMR – Regional Medical Research Center (Gorakhpur), TN Medical College – BYL Nair Hospital (Mumbai), Mahatma Gandhi Institute of Medical Sciences (Sewagram) and Government Faculty of Medicine (Nagpur).
A total of 1,600 applicants will participate in the study. Each player will administer two doses within 4 weeks. The first dose will be given on day one and the dose of the moment will be scheduled for the 29th, depending on the study design.
Click here to read Mint ePaperLivemint.com is now on Telegram. Join the Livemint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any of our emails, check your spam folder.